Based on the Eyenovia Inc stock forecast from 1 analysts, the average analyst target price for Eyenovia Inc is USD 2.00 over the next 12 months. Eyenovia Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Eyenovia Inc is Very Bearish, which is based on 0 positive signals and 6 negative signals. At the last closing, Eyenovia Inc’s stock price was USD 0.93. Eyenovia Inc’s stock price has changed by -15.48% over the past week, -41.53% over the past month and -98.41% over the last year.
No recent analyst target price found for Eyenovia Inc
No recent average analyst rating found for Eyenovia Inc
Company Overview Eyenovia Inc
Eyenovia, Inc., a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics. It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine diagnostic procedures and in conditions where short term pupil dilation is desired, and clobetasol propionate ophthalmic suspension for the treatment of post-operative pain and inflammation following ocular surgery. The company is also developing the Optejet delivery system for use in combination with its drug-device therapeutic programs and for out-licensing for use in combination with therapeutics for additional indications. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company has agreement with Formosa Pharmaceuticals. Inc. for Co-Development of Clobetasol Propionate Ophthalmic Suspension (0.05%) for the Treatment of Acute Dry Eye Disease in the U.S. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York. Read Less
Eyenovia, Inc., a commercial-stage ophthalmic pharmaceutical technology company, engages in developing a pipeline of microdose array print therapeutics. It focuses on commercializing Mydcombi (tropicamide and phenylephrine HCL ophthalmic spray) for inducing mydriasis for routine ...Read More
Frequently Asked Questions About Eyenovia Inc (EYEN) Stock
Based on ratings from 1 analysts Eyenovia Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Very Bearish. The stock has buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on EYEN's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for EYEN is USD 2.00 over the next 12 months. The maximum analyst target price is USD 2 while the minimum anlayst target price is USD 2.
Unfortunately we do not have enough data on EYEN's stock to indicate if its overvalued.
The last closing price of EYEN's stock was USD 0.93.
The most recent market capitalization for EYEN is USD 3.33M.
Based on targets from 1 analysts, the average taret price for EYEN is projected at USD 2.00 over the next 12 months.
This means that EYEN's stock price may go up by +117.39% over the next 12 months.
We can't find any ETFs which contains Eyenovia Inc's stock.
As per our most recent records Eyenovia Inc has 57 Employees.
Eyenovia Inc's registered address is 295 Madison Avenue, New York, NY, United States, 10017.
You can get more information about it from Eyenovia Inc's website at https://www.eyenovia.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
There is nothing we particularly like
What not to like
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Eyenovia Inc (EYEN) Stock
Based on ratings from 1 analysts Eyenovia Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Very Bearish. The stock has buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on EYEN's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for EYEN is USD 2.00 over the next 12 months. The maximum analyst target price is USD 2 while the minimum anlayst target price is USD 2.
Unfortunately we do not have enough data on EYEN's stock to indicate if its overvalued.
The last closing price of EYEN's stock was USD 0.93.
The most recent market capitalization for EYEN is USD 3.33M.
Based on targets from 1 analysts, the average taret price for EYEN is projected at USD 2.00 over the next 12 months.
This means that EYEN's stock price may go up by +117.39% over the next 12 months.
We can't find any ETFs which contains Eyenovia Inc's stock.
As per our most recent records Eyenovia Inc has 57 Employees.
Eyenovia Inc's registered address is 295 Madison Avenue, New York, NY, United States, 10017.
You can get more information about it from Eyenovia Inc's website at https://www.eyenovia.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for EYEN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
